|
| 백혈구 감소증이 발생한 신장이식 환자에서 GM - CSF의 사용 |
| 진동찬 , 윤영석 , 김석영 , 최의진 , 방병기 |
|
|
| Abstract |
|
Leukopenia is often occurred in kidney transplant recipients who received azathioprine (Aza) as im- munosuppressive regimen. GM-CSF can be used for early bone marrow recovery. We report the use of GM-CSF (Lucky-Biotec", Korea) in 9 cases of Aza- induced leukopenic renal transplant recipients. Nine patientss (8 male/1 female, mean 36 yr-old, mean post- tranplant follow up 18 1 months, mean serum creatinine 3 2 mg/dl) received Aza (mean 97 2 mg/day with pred- nisone 13 3 mg/day) and developed leukopenia to 1,378/ mm of WBC count. These patients were administered GM-CSF with 200-400 ng/day s.c. for 3 to 9 days after prompt cessation of Aza. Post GM-CSF therapy mean WBC count were were 8,956/mm' and no specific side effect were detected. In conclusion, GM-CSF can be useful for early bone marrow recovery in leukopenic renal transplant recipients. |
|
PDF Links
Download Citation
